183 related articles for article (PubMed ID: 26268782)
41. Safe administration of iodine-131 tositumomab after repeated infusion-related reactions to rituximab.
Hayslip J; Fenning R
Oncologist; 2007 Mar; 12(3):338-40. PubMed ID: 17405899
[TBL] [Abstract][Full Text] [Related]
42. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
[TBL] [Abstract][Full Text] [Related]
43. Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications.
Kotchetkov R; McLean J; Nay D; Gerard L; Hopkins S; Didiodato G
Int J Cancer; 2020 Oct; 147(7):1979-1986. PubMed ID: 32189328
[TBL] [Abstract][Full Text] [Related]
44. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting.
Sehn LH; Donaldson J; Filewich A; Fitzgerald C; Gill KK; Runzer N; Searle B; Souliere S; Spinelli JJ; Sutherland J; Connors JM
Blood; 2007 May; 109(10):4171-3. PubMed ID: 17244675
[TBL] [Abstract][Full Text] [Related]
45. Implementation and Evaluation of a 90-Minute Rituximab Infusion Protocol at the Richard L. Roudebush VA Medical Center.
Fenton TT; Crawford BS; Bullington SM
Fed Pract; 2020 Jul; 37(7):331-335. PubMed ID: 32908338
[TBL] [Abstract][Full Text] [Related]
46. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions.
Durham CG; Thotakura D; Sager L; Foster J; Herrington JD
J Oncol Pharm Pract; 2019 Sep; 25(6):1396-1401. PubMed ID: 30419768
[TBL] [Abstract][Full Text] [Related]
47. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
[TBL] [Abstract][Full Text] [Related]
48. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
Bonnekoh B; Schulz M; Franke I; Gollnick H
J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
[TBL] [Abstract][Full Text] [Related]
49. Implementation of an Accelerated Infusion Protocol (90-Minute Infusion) of Rituximab and Its Safety in Patients With Autoimmune Rheumatic Diseases at a Tertiary Veterans Affairs Center.
Nahra V; Panning D; Anthony D; Mattar M
Cureus; 2024 May; 16(5):e60558. PubMed ID: 38887351
[TBL] [Abstract][Full Text] [Related]
50. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
[TBL] [Abstract][Full Text] [Related]
51. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
[TBL] [Abstract][Full Text] [Related]
52. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma.
Economopoulos T; Fountzilas G; Pavlidis N; Kalantzis D; Papageorgiou E; Christodoulou C; Hamilos G; Nicolaides C; Dimopoulos M
Hematol J; 2003; 4(2):110-5. PubMed ID: 12750729
[TBL] [Abstract][Full Text] [Related]
53. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
54. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
Hainsworth JD; Raefsky EL; Greco FA
Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
[TBL] [Abstract][Full Text] [Related]
55. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.
Rule S; Collins GP; Samanta K
J Med Econ; 2014 Jul; 17(7):459-68. PubMed ID: 24720836
[TBL] [Abstract][Full Text] [Related]
56. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital.
Jung JW; Kang HR; Lee SH; Cho SH
Oncology; 2014; 86(3):127-34. PubMed ID: 24480856
[TBL] [Abstract][Full Text] [Related]
57. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.
Davis TA; White CA; Grillo-López AJ; Velásquez WS; Link B; Maloney DG; Dillman RO; Williams ME; Mohrbacher A; Weaver R; Dowden S; Levy R
J Clin Oncol; 1999 Jun; 17(6):1851-7. PubMed ID: 10561225
[TBL] [Abstract][Full Text] [Related]
58. Feasibility of rapid infusion of the initial dose of bevacizumab in patients with cancer.
Makris G; Kantzioura A; Beredima M; Karampola M; Emmanouilides C
J BUON; 2015; 20(3):923-7. PubMed ID: 26214648
[TBL] [Abstract][Full Text] [Related]
59. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
Leahy MF; Seymour JF; Hicks RJ; Turner JH
J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
[TBL] [Abstract][Full Text] [Related]
60. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.
D'Arena G; Simeon V; Laurenti L; Cimminiello M; Innocenti I; Gilio M; Padula A; Vigliotti ML; De Lorenzo S; Loseto G; Passarelli A; Di Minno MND; Tucci M; De Feo V; D'Auria F; Silvestris F; Di Minno G; Musto P
Leuk Lymphoma; 2017 Nov; 58(11):2633-2641. PubMed ID: 28367662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
